Shi-Lynne Bernard, APRN
Family · Titusville, FLNPI 1700343647
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,768 of the $6,128 with a category attached, or 61.5%. 29 manufacturers reported payments, led by Angiodynamics, Inc. at 37.2% of the total. Reporting peaked in 2022 at $2,986 and has fallen 76.1% since, to $715 in 2025. Among family clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 188 payments — averaging $32.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$2K
- Johnson & Johnson$504
- Abiomed$305
- Novartis$296
- Merck$267
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$261
- plus $2K from 23 others
What the payments were for
- Food & beverage$3,76861%
- Education$831%
- Other$2,27837%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 1 | $2,278 |
| Johnson & Johnson | 20 | $504 |
| Abiomed | 8 | $305 |
| Novartis | 16 | $296 |
| Merck | 16 | $267 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 13 | $261 |
| E.r. Squibb & Sons, L.L.C. | 21 | $248 |
| Amgen | 14 | $243 |
| Sanofi-aventis U.S. LLC | 11 | $213 |
| Pfizer | 12 | $209 |
| Boston Scientific | 10 | $190 |
| Cvrx, Inc. | 2 | $166 |
| Bayer | 8 | $156 |
| AstraZeneca | 5 | $148 |
| Boehringer Ingelheim | 6 | $140 |
| Esperion Therapeutics, Inc. | 4 | $81 |
| Lexicon Pharmaceuticals, Inc. | 3 | $71 |
| Amarin Pharma, Inc. | 3 | $59 |
| Abbott | 2 | $44 |
| Cardiovascular Systems Inc. | 2 | $41 |
| Impulse Dynamics (USA) Inc. | 1 | $31 |
| Terumo Medical Corporation | 1 | $31 |
| Arbor Pharmaceuticals, Inc. | 2 | $30 |
| Tactile Systems Technology Inc | 2 | $30 |
| Medtronic | 1 | $25 |
| Stryker | 1 | $18 |
| Shockwave Medical, Inc | 1 | $17 |
| Scpharmaceuticals Inc. | 1 | $16 |
| Bardy Diagnostics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auryon Laser System 100-120 Vac$2,278
- XARELTO$125
- Impella$116
- Barostim Neo System$112
How this compares
$6,128 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 21 | $28,753 |
| EntrestoSacubitril/Valsartan | 23 | $22,649 |
| XareltoRivaroxaban | 17 | $21,241 |
| JardianceEmpagliflozin | 29 | $19,960 |
| Losartan Potassium | 84 | $976 |
| Carvedilol | 57 | $777 |
| ClopidogrelClopidogrel Bisulfate | 31 | $476 |
| Potassium Chloride | 26 | $446 |
| Ezetimibe | 12 | $422 |
| Atorvastatin Calcium | 34 | $275 |
| Lisinopril | 27 | $269 |
| Metoprolol Succinate | 14 | $230 |
| Furosemide | 41 | $155 |
| Metoprolol Tartrate | 22 | $154 |
| Amlodipine Besylate | 19 | $143 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $209 | $28,75321 claims |
| NovartisEntresto | $296 | $22,64923 claims |
| Johnson & JohnsonXarelto | $504 | $21,24117 claims |
| Boehringer IngelheimJardiance | $140 | $19,96029 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 14,618 family providers in Florida.
Other family in Titusville
- Lewis HarringtonTampa$954K
- Danielle PharesFt Lauderdale$713K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
- Deena RodneyMaitland$323K
- Yamila MelendezMiami$212K
- Holly BoydLand O Lakes$200K
- Rachael BuschLoxahatchee$189K
- Victor Tatis de la NuezMiramar$161K
- Ronda CrewsJax Bch$155K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.